康维德的争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 2 条
2026
发明人David Parsons就Aquacel专利收益起诉Convatec，索赔至多3.66亿英镑
提起诉讼
分析化学家David Parsons博士曾于1991年至2023年任职于富时100指数成分公司Convatec Ltd，目前在英国高等法院起诉这家医疗产品公司，依据《1977年专利法》第40条索赔至多3.66亿英镑，声称以其署名的、用于Convatec Aquacel抗菌伤口敷料的专利为雇主创造了'杰出'收益。Convatec正在抗辩该索赔，主张仅'杰出'的单项发明才可获得补偿，而非将多项专利合并考量；本案本周上诉至上诉法院，判决可能择日作出，高等法院为期六周的庭审定于2028年举行。
当事方说明的目的. Dr Parsons寻求至多3.66亿英镑的补偿并要求分享利润，理由是其专利发明为ConvaTec创造了'杰出'收益。
品牌回应
否认 — Convatec
But Convatec is fighting the claim, which reached the Court of Appeal this week as the two sides argued over the issues to be determined when it reaches trial before the High Court in 2028.
来源摘录
Analytical chemist Dr David Parsons worked for FTSE100-listed Convatec Ltd for more than 30 years, having joined the London-based medical products and technologies company in 1991.
But Convatec is fighting the claim, which reached the Court of Appeal this week as the two sides argued over the issues to be determined when it reaches trial before the High Court in 2028.
Having left in 2023, Dr Parsons, of Hoylake, Merseyside, is now suing for compensation of up to £366m at the High Court, claiming his work created an "outstanding" benefit for his employer.
2023
对继续在俄罗斯市场活动的批评
康维德被列入“离开俄罗斯”项目，该项目追踪继续在俄罗斯运营的公司。批评者认为，持续的销售活动间接支持了俄罗斯经济和政府。公司已于2022年暂停其俄罗斯销售团队并关闭白俄罗斯制造工厂，但对其在俄罗斯更广泛存在的批评仍在继续。